July 31, 2025 - Alerts and Newsletters

        Legal Readiness for AI in Healthcare: A Provider’s Quick Guide

        Artificial Intelligence (AI) continues to revolutionize industries and is poised to bring transformative change in healthcare delivery, drug discovery, diagnostics, and data analysis and communication. This technology is exciting and offers tremendous possibilities for both patients and providers. With new technologies, however, there are new risks and rewards to consider. Healthcare providers must carefully consider the legal implications of incorporating AI tools into their operations and clinical practices. A few key areas stand out at present:

        • Patient data privacy and security remain paramount. Healthcare providers are subject to stringent federal and state regulations, such as the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Any AI system with access to Protected Health Information (PHI) must meet rigorous standards for data protection. As part of compliance with the Security Rule and the Privacy Rule, AI tools that process PHI should be designed and/or implemented in a manner that follows HIPAA use and disclosure rules, and employs robust encryption, access controls, and compliance checks to avoid potential breaches and costly penalties.
        • The adoption of AI raises important questions about malpractice liability and accountability. The accuracy and reliability of AI-powered diagnostic tools, treatment recommendations, or patient monitoring systems are critical to patient outcomes. Institutional-level providers, group practices, and individual practitioners must carefully assess the risk of error and ensure that appropriate safeguards are in place, such as human oversight and ongoing validation, to minimize the likelihood of errors. Additionally, healthcare providers may need to revise their malpractice insurance policies to address potential legal liability if AI tools contribute to adverse patient outcomes. Providers and insurers will need to reach a consensus as to which responsibilities lie with the AI software developers, the healthcare providers, or both.
        • Healthcare providers must also be mindful of regulatory approvals and ethical considerations when integrating AI into clinical practice. AI-based medical devices or software may require approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) before being used in patient care. Additionally, healthcare providers must ensure that AI algorithms are unbiased and transparent in their decision-making processes. This may require ensuring that regular audits are conducted, using true random samples of patient populations in training data, and implementing safeguards to prevent algorithmic discrimination or other outcomes that violate established and accepted provider standards regarding the rights, informed consent, and well-being of patients. Navigating these complex legal and ethical considerations is essential for healthcare stakeholders and businesses of all kinds to successfully and safely adopt AI technologies.

        For more information and legal insights as to how AI may affect your business, please contact Andrew A. Ferrer in Verrill’s Boston office or another member of our Artificial Intelligence & Emerging Technologies group.

        Firm Highlights

        Blog

        Maine’s Noncompete Statute is Reshaped for Health Care Workers: What You Need to Know

        Employers of individuals who are licensed under state law to perform, or provide, health care services in the State of Maine should be prepared for...
        Media Mentions

        Steven Davis Featured in the Environmental Business Journal

        Steven Davis, President of Verrill Strategic Consulting, was recently interviewed and featured in the Environmental Business Journal, Volume 39...
        Blog

        What is a Bonus for Purposes of ERISA?

        An ongoing dispute about a Department of Labor advisory opinion published last September raises a basic but unanswered question under the ERISA: What...
        Media Mentions

        Verrill Recognized by WMTW for Partnership Supporting Hunger Relief in Maine

        Verrill was recently featured in coverage by WMTW News 8 for its role in a collaborative effort to combat food insecurity across southern...
        Press Releases

        33 Verrill Attorneys, Across Four Offices, Recognized in the 2026 Chambers USA Guide

        BOSTON, Massachusetts, PORTLAND, Maine, WESTPORT, Connecticut, and WASHINGTON, D.C. – Verrill has been recognized as a Leading Firm in 14...
        Blog

        Will the Knicks Beat the Spurs? (Are Prediction Market Event Contracts Gambling?)

        For those of you who like to keep score, currently 18 states are engaged in litigation over prediction markets, such as Kalshi and Polymarket,...
        Alerts and Newsletters

        DOJ Announces Faster Review and Enhanced Enforcement for Benefits-Fraud FCA Matters

        On May 27, 2026, the U.S. Department of Justice (DOJ) Civil Division issued a new memorandum, “Accelerating Review and Enhancing Enforcement in...
        Alerts and Newsletters

        DOJ Announces Minnesota Health Care Fraud Takedown; Signals Intensified Medicaid Enforcement Nationwide

        On May 21, the Department of Justice (“DOJ”) announced a first-of-its kind Minnesota Health Care Fraud Takedown charging 15 defendants, including...
        Media Mentions

        Lauren Galvin Quoted in Massachusetts Lawyers Weekly on Arbitration and Anti-SLAPP Protections

        Verrill Partner Lauren Galvin was recently featured in a Massachusetts Lawyers Weekly article highlighting a notable Superior Court decision...
        Blog

        Section 530A Accounts: What Employers Should Consider Before Offering Contributions to “Trump” Accounts

        Section 530A accounts, commonly referred to as Trump accounts, have attracted attention since the enactment of the One Big Beautiful Bill Act in...
        Blog

        Navigating PBM Reform: Regulatory Changes, Market Shifts, and Practical Guidance for ERISA Fiduciaries

        Pharmacy Benefit Manager (“PBM”) arrangements have long relied on rebates with limited transparency into true drug costs. Recent regulatory and...
        Blog

        DOL’s Proposed Regulation on Selecting Alternative Investments: Broad Implications for 401(k) and 403(b) Plan Fiduciaries

        On March 30, 2026, the Department of Labor issued a proposed regulation purporting to implement an executive order to expand access to “alternative...